Merck has stopped three Phase 3 nemtabrutinib trials after a review found that the blood cancer drug’s potential benefits may not outweigh its risks.
Merck Stops Nemtabrutinib Trials After Safety Review
Merck has stopped three Phase 3 nemtabrutinib trials after a review found that the blood cancer drug’s potential benefits may not outweigh its risks.